Chronic myelocytic leukemia therapeutic pipeline analysis is expected to grow rapidly due to the increasing prevalence of the disease, globally. Some of the main factors driving the pipeline analysis for chronic myelocytic leukemia include increasing aging population and rising prevalence of chronic myelocytic leukemia, and increasing health awareness. Chronic myelocytic leukemia have high incidence rate in men and is the second most common type of cancer occurring in male adults. Women, above 50 years of age are at high risk to develop chronic myelocytic leukemia.
Chronic myeloid leukemia is the tumour that occurs in blood cells and bone marrow, which is the soft parts inside bones where blood cells are produced. Chronic myelocytic leukemia usually occurs in middle-aged or older adults. It occurs due to the swapping of DNA between chromosome 9 nine and chromosome 22. The resultant abnormal chromosome is known as Philadelphia chromosome. This swapping forms a new gene, BCR-ABL which is the type of protein, tyrosine kinase. This protein causes chronic myelocytic leukemia cells to grow and reproduce uncontrollable manner. One of the main cause of chronic myelocytic leukemia is exposure to high radiation. The symptoms of chronic myelocytic leukemia include stroke, dizziness, change in vision, swollen glands, high fever, bruises, weight loss, pain in bones, short of breath and night sweats. Chronic myeloid leukemia can be diagnosed by performing a bone marrow test, complete blood count, FISH test and ultrasound. The treatment for chronic myeloid leukemia includes drug therapy and stem cell transplant.
Novartis AG is developing a drug by the name Nilotinib for the improvement of Philidelphia positive chronic myeloid leukaemia. Nilotinib is being developed as a small molecule, which inhibits BCR-ABL tyrosine kinase. It has also received orphan drug designation by the U.S. Food and Drug Administration for chronic myeloid leukaemia and gastrointestinal stromal tumors. ARIAD Pharmaceuticals, Inc. is currently developing Ponatinib, which is in Phase III stage of clinical trial for second line of therapy. Ponatinib is a small molecule which effectively inhibits BCR-ABL tyrosine kinase. Hybrigenics Corporation is developing Inecalcitol for chronic myeloid leukemia patients. It is currently in Phase II stage of development and acts as a small molecule which is a calcitriol receptor agonists. It has also received orphan drug designation by the U.S. Food and Drug Administration for acute myeloid leukaemia and chronic lymphocytic leukaemia. Fusion Pharma LLC is in the process of developing PF-114, which is in Phase I/II clinical trial, and is a BCR-ABL tyrosine kinase inhibitors. Bio-Path Holdings is also developing a drug for chronic lymphocytic leukaemia patients by the name BP-1001. It acts as a MAP kinase inhibitor and has also received orphan drug designation by the U.S. Food and Drug Administration for acute myeloid leukaemia and chronic myeloid leukaemia.
Some of the companies having a pipeline of chronic myelocytic leukemia therapeutics include Bristol Myers Squibb Company, ARIAD Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hospira, Prism Pharma, Incyte Corp., Otsuka Pharmaceutical Co., Ltd., Bio-Path Holdings, Hybrigenics Corporation, Fusion Pharma LLC.